Key Proteo Announces New President and CEO
Key Proteo Appoints Mark Willig as President and Chief Executive Officer
SEATTLE, WA – August 21, 2023 – Key Proteo, a pioneer in novel peptide screening for newborn babies to aid in the early detection of treatable genetic disorders, today announced the appointment of Mark Willig as President and Chief Executive Officer. Mr. Willig is an accomplished executive and board advisor in the life sciences and medical technology space with over 25 years of C-suite experience and success in building, restructuring and catalyzing growth at early-stage and mature organizations.
Mr. Willig possesses a proven track record and is an adept business leader that has built global businesses through growing or restructuring organizations to drive exponential growth. He has vast experience with the development and execution of highly focused commercial and business development strategies and product portfolio diversification initiatives that have created new revenue streams, improved patient outcomes and enhanced shareholder value. Mr. Willig has brought his leadership to Fortune 100 companies such as Thermo Fisher Scientific and Abbott Laboratories. He has also led three companies to acquisition including early-stage companies such as PrognostiX as CEO and turnarounds including Exiqon A/S as General Manager and Specialty Laboratories as Chief Commercial Officer. Mr. Willig currently serves on three Boards and was most recently the Chief Executive Officer at Alveo Technologies where he drove the organization to its first regulatory approval while raising over $17 million in Series B funding.
“We are pleased to welcome Mark to the Key Proteo family at an important moment in our drive towards commercialization of our novel proteomic-based in-vitro diagnostic testing for newborn screening that can expand the scope of detectable genetic disorders with more accuracy, effectiveness, and efficiency than current newborn screening methods,” said Dr. Steve (Sihoun) Hahn, co-founder and Board Chair of Key Proteo. “Our clinical research provides promising evidence of the diagnostic potential of this approach, and we are excited that Mark shares our passion to enhance newborn screening programs to allow for the efficient diagnosis of genetic disorders that can become fatal without effective and early treatment. We look forward to benefitting from his experience as he assumes his role overseeing Key Proteo’s scientific, clinical, and commercial operations.”
“Key Proteo is bringing a unique, differentiated approach to the early detection of genetic disorders among newborns and has assembled a high-caliber network of colleagues, collaborators, and partners to deliver on the vision of early detection and treatment,” said Mr. Willig. “I am passionate about building businesses based on impactful, innovative clinical products, and am excited to be part of a company with such tremendous potential.”
ABOUT KEY PROTEO
Key Proteo, a Seattle-based proteomic diagnostics company, is on a mission to expand newborn screening programs through the early identification of treatable genetic conditions, enabling early intervention that can improve outcomes and quality of life for these patients. Key Proteo’s patent-pending Immuno-SRM platform and associated diagnostic kits can perform targeted proteomic analysis of extremely low abundance peptide biomarkers from a few drops of blood. This proprietary technology expands the scope of detecting previously undetectable genetic disorders in newborns with high accuracy, effectiveness and efficiency, and has demonstrated faster turnaround times and lower costs when compared to next-generation sequencing (NGS).
CONTACT
Sean Sandin
Director, Business Development
(206) 339-7515
###
